Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK5 | Q8IW41 | 10/20 | 0.55 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 2/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | FYN | P06241 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.34 |
| ▸ | FEN1 | P39748 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.34 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14162753 | 0.90 | MAPKAPK5 (0.55) | MAPKAPK5AURKAAURKBSYKPIK3CA | |
| SCHEMBL14162745 | 0.89 | MAPKAPK5 (0.58) | MAPKAPK5AURKAAURKBSYKALDH1A1 | |
| SCHEMBL10133649 | 0.86 | MAPKAPK5 (0.58) | MAPKAPK5AURKAAURKBPIK3CAFYN | |
| SCHEMBL12424127 | 0.85 | MAPKAPK5 (0.47) | MAPKAPK5AURKAAURKBPIK3CALRRK2 | |
| SCHEMBL12618841 | 0.85 | MAPKAPK5 (0.63) | MAPKAPK5SYKPIK3CAFYNLRRK2 | |
| SCHEMBL10134371 | 0.83 | MAPKAPK5 (0.75) | MAPKAPK5SYKFYNLRRK2 | |
| SCHEMBL14162554 | 0.82 | MAPKAPK5 (0.55) | MAPKAPK5AURKBSYKPIK3CALRRK2 | |
| SCHEMBL10133603 | 0.81 | MAPKAPK5 (0.46) | MAPKAPK5AURKAAURKBPIK3CAALOX5AP | |
| SCHEMBL10133592 | 0.80 | MAPKAPK5 (0.49) | MAPKAPK5AURKAAURKBALDH1A1 | |
| SCHEMBL12957953 | 0.80 | MAPKAPK5 (0.55) | MAPKAPK5AURKBPIK3CAFYNLRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120010206-A1 | IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS N. V. (BE) | 2012-01-12 | — | — | US | disclosed |
| US-20120010206-A1 | IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS N. V. (BE) | 2012-01-12 | — | — | US | disclosed |
| US-7951818-B2 | Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2011-05-31 | — | — | US | disclosed |
| US-20090048245-A1 | Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010206-A1 | IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | COL2A1, MMP1, COL1A1 | MAPKAPK5 19/4885AURKA 3833/4885AURKB 3410/4885 |
| US-20090048245-A1 | Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases | COL2A1, MMP1, COL1A1 | MAPKAPK5 19/4885AURKA 3833/4885AURKB 3410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.